Donate Toggle Menu

New developments are now foreseen with the resurgence of immune checkpoint blockers in mRCC. The development of antibodies against the PD-1 pathway, either alone or in combination, may represent the potential next clinical breakthrough. In addition, the understanding of resistance mechanisms to agents targeting angiogenesis has identified some potential new targets such as Ang-2, FGFR, MET, and others.